DOJ Reclassifies Medical Marijuana to Schedule III
Medical marijuana reclassification 2026
The United States Department of Justice formally reclassified state-licensed medical marijuana from Schedule I to Schedule III on Thursday, April 23, 2026. Acting Attorney General Todd Blanche signed the historic order, which marks the most significant shift in federal cannabis policy since the implementation of the Marihuana Tax Act of 1937.
By moving cannabis to the less-restricted Schedule III category, the federal government officially recognizes the substance’s accepted medical utility for the first time. The decision follows a directive from President Donald Trump issued in late 2025 to expeditiously resolve the long-standing regulatory deadlock that had persisted across previous administrations.
This reclassification applies specifically to marijuana products distributed through regulated state medical programs and those approved by the Food and Drug Administration. Official documentation and detailed legal reasoning for the shift are available through the U.S. Department of Justice and reported by the Associated Press.
This major policy change provides an immediate economic windfall for state-licensed cannabis businesses by removing the punitive tax restrictions known as Section 280E. Previously, these companies were prohibited from deducting standard business expenses on their federal tax returns because they dealt in Schedule I substances. The reclassification to Schedule III allows medical marijuana producers and dispensaries in 40 states to operate under the same tax rules as traditional retail businesses.
This shift is expected to save the industry billions of dollars annually and encourage new investment in the sector. Furthermore, the order establishes an expedited registration process for state-licensed entities to work directly with the Drug Enforcement Administration. This framework is expected to drastically lower the barriers to entry for clinical research into the safety and efficacy of various cannabis strains. Industry leaders and financial analysts are monitoring the impact of these changes through Reuters for real-time market updates.
Despite the federal reclassification, the Justice Department emphasized that the move does not constitute the total decriminalization or legalization of recreational marijuana. Marijuana and marijuana-derived products that are distributed outside of state-licensed medical frameworks will continue to be classified as Schedule I drugs with high potential for abuse. Federal authorities maintain that they will continue to prosecute illegal trafficking and the distribution of cannabis to minors.
The administration also announced that a new administrative hearing process will begin in June 2026 to consider broader rescheduling or potential future legislative reforms. Advocates for cannabis reform have praised the move as a long-overdue alignment of federal law with the reality of medical practice across most of the United States. Further analysis of the global implications of this shift can be found via The Guardian world news reporting as the legal landscape continues to evolve.
